Aneurysmal Subarachnoid Hemorrhage Market Size, Share, Competitive Landscape and Trend Analysis Report, by Therapy Type and, by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Aneurysmal subarachnoid hemorrhage is a condition wherein a brain aneurysm ruptures, resulting in bleeding into the subarachnoid space. In severe cases, bleeding may cause brain damage leading to paralysis or coma and even death. The National Institutes of Health (NIH) has stated that aneurysmal subarachnoid hemorrhage (SAH) is a worldwide health burden and possesses high fatality and permanent disability rates.

The major factors that drive the global aneurysmal subarachnoid hemorrhage market are rise in incidence of road accidents leading to head injuries and rupture of cerebral aneurysm cases, causing aneurysmal subarachnoid hemorrhage; improved healthcare infrastructure; and growth in awareness about aneurysmal subarachnoid hemorrhage. However, stringent regulatory regulations and high cost of aneurysmal subarachnoid hemorrhage diagnosis products restrain the market growth. Furthermore, technological advancement in healthcare sector and willingness to adopt innovative products for emergency care are expected to provide numerous opportunities for market growth in the future.

The global aneurysmal subarachnoid hemorrhage market is segmented based on therapy type, end user, and region. On the basis of therapy type, it is divided into computed tomography (CT) scan, magnetic resonance imaging (MRI), lumbar puncture, xanthochromia, cerebral angiography, and transcranial Doppler ultrasound. Based on end user, it is categorized into hospitals, clinics, and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market are Edge Therapeutics, Inc., Actelion Pharmaceuticals Ltd., Arbor Pharmaceuticals Inc., Mayfield Brain & Spine, Europa Group, GE Healthcare, Koninklijke Philips N.V., Siemens AG, Trivitron Healthcare, and Toshiba Medical Systems Corporation.

Key Benefits

• The study provides an in-depth analysis of the global aneurysmal subarachnoid hemorrhage market with current trends and future estimations to elucidate the imminent investment pockets.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale are provided.
• Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

  Aneurysmal Subarachnoid Hemorrhage Market Report Highlights

Aspects	Details
By Therapy Type	Computed Tomography Scan Magnetic Resonance Imaging Lumbar Puncture Xanthochromia Cerebral Angiography Transcranial Doppler Ultrasound
By End User	Hospitals Clinics Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Trivitron Healthcare, Actelion Pharmaceuticals Ltd., GE Healthcare, Siemens AG, Europa Group, Mayfield Brain & Spine, Toshiba Medical Systems Corporation, Arbor Pharmaceuticals Inc., Koninklijke Philips N.V., Edge Therapeutics, Inc.

^*Terms and Conditions Apply